{"entity":{"id":"nct07199764","kind":"trial","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","aka":["IGNITE"],"tldr":"A phase 2 trial of mitazalimab in pancreatic cancer, run by University of Pennsylvania, now recruiting.","summary":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer is a phase 2, interventional study registered as NCT07199764 by University of Pennsylvania, with a registry enrolment figure of 100 participants, started 2025-11-25 and due to reach its primary completion in 2027-10. Interventions recorded: Odetiglucan; Mitazalimab. Conditions listed: Pancreatic Ductal Adenocarcinoma. Primary outcome: Median progression-free survival (mPFS) of 7.5 months in Cohort A. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma that is either locally advanced and unresectable, or metastatic\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07199764","url":"https://clinicaltrials.gov/study/NCT07199764"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["mitazalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07199764","phase":"2","setting":"IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma","sponsor":"University of Pennsylvania","participation":[{"nct":"NCT07199764","source":"https://clinicaltrials.gov/study/NCT07199764","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"faaef57a378d5049bcb201c464d7d9b3c0ff083ef8deeb4197839c0f1134bd03","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-10","leadSponsor":"University of Pennsylvania","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":100,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2025-11-25","startedType":"actual","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07199764/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"drug":[{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}